Quinoline derivatives and their use as 5-ht6 ligands
Disclosed are novel quinoline compounds of formula (I), processes for their preparation, compositions containing them and their use in the treatment of CNS disorders.
1. A compound having the formula:
or a pharmaceutically acceptable salt thereof.
2. A compound which is 3-phenylsulfonyl-8-piperazin-1-yl-quinoline.
3. A method of treating a cognitive memory disorder which comprises administering a therapeutically effective amount of the compound, or pharmaceutically acceptable salt thereof, according to claim 1 to a human in need thereof, wherein the cognitive memory disorder is selected from age related cognitive decline, mild cognitive impairment, and cognitive deficits in schizophrenia.
4. A method of treating a cognitive memory disorder which comprises administering a therapeutically effective amount of the compound according to claim 2 to a human in need thereof, wherein the cognitive memory disorder is selected from age related cognitive decline, mild cognitive impairment, and cognitive deficits in schizophrenia.
5. A crystalline form of the compound according to claim 2 , wherein said crystalline form provides an X-ray powder diffraction pattern substantially in accordance with FIG. 6 .
6. A crystalline form of the compound according to claim 2 , wherein said crystalline form provides a Raman spectrum substantially in accordance with FIG. 5 .
7. A crystalline form of the compound according to claim 2 , wherein said crystalline form provides an infra red spectrum substantially in accordance with FIG. 4 .
8. A method of treating Alzheimers disease comprising administering a therapeutically effective amount of the compound, or pharmaceutically acceptable salt thereof, according to claim 1 to a human in need thereof.
9. A method of treating Alzheimers disease comprising administering a therapeutically effective amount of the compound according to claim 2 to a human in need thereof.
10. A pharmaceutical composition comprising the compound, or pharmaceutically acceptable salt thereof, according to claim 1 and a pharmaceutically acceptable carrier or excipient.
11. A pharmaceutical composition comprising the compound according to claim 2 and a pharmaceutically acceptable carrier or excipient.